Comparison of Tropisetron with Ondansetron in the Prevention of Cisplatin-induced Nausea and Vomiting / 대한암학회지
Journal of the Korean Cancer Association
;
: 332-339, 1997.
Article
Dans Coréen
| WPRIM
| ID: wpr-123090
ABSTRACT
PURPOSE:
Tropisetron (Nabovan (R)) is a new specific 5-HT3 receptor antagonist with a long terminal half life in plasma and high bioavailability after oral intake. We compared the antiemetic effectiveness and tolerability of tropisetron with ondansetron in the highly emetogenic chemotherapy (including cisplatin > or =50 mg/m2). MATERIALS ANDMETHODS:
Thirty-nine patients were administered in a randomized, multicenter, open, cross-over study and received either tropisetron plus dexamethasone (n=31) or ondansetron plus dexamethasone (n=34) during six days of two successive cycles of chemotherapy.RESULTS:
Total control of vomiting with either Ondansetron or tropisetron was 94.2 % vs 93.5 % in D1 (P=0.157); 90.6 % vs 93.1 % in D2 (P=0.18); 90.3 % vs 93.1 % in D3 (P=0.655); 96.4% vs 96.4 % in D4 (P=0.157); 96.4 % vs 100 % in D5 (P=0.317); 96.4 % vs 100% in D6, respectively. The duration of nausea showed significant decreasements in tropisetron at D5 and D6 (P=0.025, P=0.03, respectively), but the severity of nausea and performance status showed no significance. Headache and constipation were the most common side effects in both groups.CONCLUSION:
There was no significant difference in efficacy and tolerability between tropisetron and ondansetron in the cisplatin-based chemotherapy.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Plasma sanguin
/
Vomissement
/
Dexaméthasone
/
Biodisponibilité
/
Cisplatine
/
Ondansétron
/
Études croisées
/
Constipation
/
Récepteurs sérotoninergiques 5-HT3
/
Traitement médicamenteux
Type d'étude:
Essai clinique contrôlé
Limites du sujet:
Humains
langue:
Coréen
Texte intégral:
Journal of the Korean Cancer Association
Année:
1997
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS